Description

Technical Parameters

Introduction

raws

product-1400-1400

Products Description

#### Overview

Dutasteride is a potent 5α-reductase inhibitor widely used to treat benign prostatic hyperplasia (BPH). Its raw material powder is the core component of pharmaceutical preparations, with high purity and specific physical and chemical properties. This article will systematically analyze Dutasteride raw materials from the aspects of chemical properties, pharmacological effects, production process, quality control, application fields and market status.

### 1. Chemical properties and structure

1. **Basic information**

- **CAS number**: 164656-23-9

- **Molecular formula**: C27H30F6N2O2

- **Molecular weight**: 528.54 g/mol

- **IUPAC name**: (5α,17β)-N-{2,5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide

2. **Chemical structure**

Dutasteride belongs to 4-azasteroid compounds, and its structure contains:

- Steroid skeleton (androstane derivative)

- Trifluoromethylphenyl substituent

- Amide bond and keto functional group

3. **Physical and chemical properties**

- **Appearance**: White to off-white crystalline powder

- **Solubility**: Almost insoluble in water, easily soluble in organic solvents (such as methanol, ethanol, DMSO)

- **Melting point**: 242–250°C (decomposition)

- **Stability**: Need to be stored away from light, stable under dry conditions, easy to absorb moisture.

### 2. Pharmacological effects and clinical advantages

1. **Mechanism of action**

Dutasteride blocks the conversion of testosterone to dihydrotestosterone (DHT) by inhibiting **5α-reductase type I and type II isozymes**, thereby reducing the level of DHT in the prostate (up to 90% or more), reducing the volume of the prostate, and improving urine flow rate.

2. **Core advantages**

- **Dual inhibition**: Compared with finasteride, which only inhibits type II enzymes, dutasteride's inhibition of type I enzymes makes its efficacy more significant.

- **Long-term effect**: The half-life is about 5 weeks, and it can be administered once a day, with high patient compliance.

- **Potential for expansion of indications**: In addition to BPH, studies have shown that it may be effective for male androgenetic alopecia (AGA), but further clinical verification is needed.

3. **Pharmacokinetics**

- **Bioavailability**: About 60% (taking with a high-fat meal can improve absorption).

- **Metabolic pathway**: Mainly metabolized by CYP3A4 enzyme, excreted mainly in feces.

### 3. Production process and quality control

1. **Synthesis route**

The synthesis of dutasteride usually adopts multi-step reactions, and the key steps include:

- **Starting material**: Using androstenedione as the raw material, the nitrogen heterocycle is introduced through oxidation and amidation.

- **Fluorination reaction**: Substituents are introduced on the trifluoromethylbenzene ring through nucleophilic substitution.

- **Purification process**: Recrystallization or chromatography is used to improve purity.

2. **Key intermediates**

- Intermediate A: 17β-carboxylic acid derivatives

- Intermediate B: trifluoromethylaniline derivatives

3. **Quality control standards**

According to the United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP), the main test indicators include:

- **Purity**: HPLC determination of the main component ≥ 99.0%.

- **Impurities**: Single impurity ≤ 0.1%, total impurity ≤ 0.5%.

- **Residual solvents**: Comply with ICH Q3C guidelines (such as methanol < 3000 ppm).

- **Microbial limits**: Must meet the requirements of sterile APIs.

### 4. Application areas and formulation development

1. **Approved indications**

- **Benign prostatic hyperplasia (BPH)**: 0.5 mg capsules (trade name Avodart®), can be used alone or in combination with α-receptor blockers.

- **Prostate cancer prevention**: Some clinical trials support its ability to reduce the incidence of low-risk prostate cancer.

2. **Off-label application**

- **Hair loss treatment**: Off-label use for AGA, but potential side effects (such as sexual dysfunction) need to be weighed.

3. **Dosage form innovation**

- Micronization technology: Improve the dissolution rate of APIs and enhance bioavailability.

- Long-acting injections: The sustained-release preparations under study can reduce the frequency of medication.

### 5. Market status and competition landscape

1. **Global market size**

In 2023, the global dutasteride API market size will be approximately US$120 million, with a compound annual growth rate (CAGR) of approximately 4.5%, mainly driven by the growth in BPH demand driven by aging.

2. **Major manufacturers**

- **Original research company**: GlaxoSmithKline (GSK), which holds the patent for Avodart® until 2025.

- **Generic drug manufacturers**: Sun Pharma in India, Zhejiang Xianju Pharmaceutical in China, etc.

3. **Regional Market**

- **North America**: occupies the largest share (about 45%), and medical insurance coverage promotes its use.

- **Asia Pacific**: fastest growing, India and China are the main exporters of APIs.

### 6. Safety and Regulatory Dynamics

1. **Adverse Reactions**

- Common: decreased libido, ejaculation disorder (incidence <5%).

- Rare: depression, male breast cancer (controversial risk, long-term monitoring required).

2. **Regulatory Requirements**

- **FDA Black Box Warning**: pregnant women may cause fetal malformation if exposed, which should be strictly avoided.

- **EMA Recommendation**: Regularly monitor prostate-specific antigen (PSA) levels.

### 7. Future Research Directions

1. **Development of new dosage forms**: such as transdermal patches and nanoparticle delivery systems.

2. **Combination therapy**: explore the potential for prostate cancer treatment in combination with anti-androgen drugs.

3. **Bioequivalence study**: promote the launch of generic drugs in more countries.

### Conclusion

Dutasteride API plays an important role in the treatment of urinary system diseases due to its unique dual inhibition mechanism and significant efficacy. With the optimization of production process and the expansion of new indications, its market prospects are broad, but it needs to continue to pay attention to long-term safety and innovative formulation development.